{"created":"2023-05-15T16:49:29.008785+00:00","id":26957,"links":{},"metadata":{"_buckets":{"deposit":"b871e0ba-e207-4856-a006-2d68857ab7d9"},"_deposit":{"created_by":6,"id":"26957","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"26957"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00026957","sets":["2014:2015"]},"author_link":["120029","120030","120031","120033","120032"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-10-25","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageStart":"1989789","bibliographicVolumeNumber":"10","bibliographic_titles":[{"bibliographic_title":"OncoImmunology"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Human Vγ2Vδ2 (also termed Vγ9Vδ2) T cells play important roles in microbial and tumor immunity by monitoring foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis. Accumulation of isoprenoid metabolites after bisphosphonate treatment allows Vγ2Vδ2 T cells to recognize and kill tumors independently of their MHC expression or burden of non-synonymous mutations. Clinical trials with more than 400 patients show that adoptive immunotherapy with Vγ2Vδ2 T cells has few side effects but has resulted in only a few partial and complete remissions. Here, we have tested Vγ2Vδ2 T cells for expression of inhibitory receptors and determined whether adding PD-1 checkpoint blockade to adoptively transferred Vγ2Vδ2 T cells enhances immunity to human PC-3 prostate tumors in an NSG mouse model. We find that Vγ2Vδ2 T cells express PD-1, CTLA-4, LAG-3, and TIM-3 inhibitory receptors during the 14-day ex vivo expansion period, and PD-1, LAG-3, and TIM-3 upon subsequent stimulation by pamidronate-treated tumor cells. Expression of PD-L1 on PC-3 prostate cancer cells was increased by co-culture with activated Vγ2Vδ2 T cells. Importantly, anti-PD-1 mAb treatment enhanced Vγ2Vδ2 T cell immunity to PC-3 tumors in immunodeficient NSG mice, reducing tumor volume nearly to zero after 5 weeks. These results demonstrate that PD-1 checkpoint blockade can enhance the effectiveness of adoptive immunotherapy with human γδ T cells in treating prostate tumors in a preclinical model.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"OncoImmunology, 10(1), art. no. 1989789; 2021","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Taylor & Francis Group, LLC."}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1080/2162402X.2021.1989789","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2162-402X","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nada, Mohanad H."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Wang, Hong"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hussein, Auter J."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tanaka, Yoshimasa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Morita, Craig T."}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-12-23"}],"displaytype":"detail","filename":"OncoImmunology10_1989789.pdf","filesize":[{"value":"2.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"OncoImmunology10_1989789.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/26957/files/OncoImmunology10_1989789.pdf"},"version_id":"a70e451c-3aa4-4d2b-aed3-4aced58d5192"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Adoptive immunotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":"programed cell death 1","subitem_subject_scheme":"Other"},{"subitem_subject":"receptor","subitem_subject_scheme":"Other"},{"subitem_subject":"prostatic","subitem_subject_scheme":"Other"},{"subitem_subject":"neoplasms","subitem_subject_scheme":"Other"},{"subitem_subject":"inhibitory T cell","subitem_subject_scheme":"Other"},{"subitem_subject":"receptors","subitem_subject_scheme":"Other"},{"subitem_subject":"combined","subitem_subject_scheme":"Other"},{"subitem_subject":"modality therapy","subitem_subject_scheme":"Other"},{"subitem_subject":"human γδ T cells","subitem_subject_scheme":"Other"},{"subitem_subject":"Vγ2Vδ2 T cells","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer"}]},"item_type_id":"2","owner":"6","path":["2015"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-12-23"},"publish_date":"2021-12-23","publish_status":"0","recid":"26957","relation_version_is_last":true,"title":["PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer"],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-05-15T20:04:42.630470+00:00"}